TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Limited announced the completion of issuing 401,676,129 ordinary shares and 277,666,667 options, as well as 1,396,999 ordinary shares from employee performance rights. This issuance was conducted without disclosure to investors under specific provisions of the Corporations Act, and the company confirmed compliance with relevant regulatory requirements. The move is part of AdAlta’s strategic financial operations, potentially impacting its market positioning and shareholder value.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited is a company operating in the biotechnology industry, focusing on developing innovative therapeutic products. The company is known for its work on i-body technology, which is used to develop treatments for various diseases, and it is listed on the Australian Securities Exchange under the code 1AD.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.